Beyond antibodies: ankyrins and DARPins. From basic research to drug approval
- 1 April 2020
- journal article
- review article
- Published by Elsevier in Current Opinion in Pharmacology
- Vol. 51, 93-101
Abstract
No abstract availableKeywords
This publication has 40 references indexed in Scilit:
- Designed Ankyrin Repeat Proteins (DARPins): Binding Proteins for Research, Diagnostics, and TherapyAnnual Review of Pharmacology and Toxicology, 2015
- Intravitreal Aflibercept (VEGF Trap-Eye) in Wet Age-related Macular DegenerationOphthalmology, 2012
- Ranibizumab and Bevacizumab for Neovascular Age-Related Macular DegenerationNew England Journal of Medicine, 2011
- Biopharmaceutical drug targeting to the brainJournal of Drug Targeting, 2010
- Efficient Selection of DARPins with Sub-nanomolar Affinities using SRP Phage DisplayJournal of Molecular Biology, 2008
- DARPins: A new generation of protein therapeuticsDrug Discovery Today, 2008
- Ranibizumab for Neovascular Age-Related Macular DegenerationNew England Journal of Medicine, 2006
- Intracellular Kinase Inhibitors Selected from Combinatorial Libraries of Designed Ankyrin Repeat ProteinsJournal of Biological Chemistry, 2005
- Somatic diversification of variable lymphocyte receptors in the agnathan sea lampreyNature, 2004
- Hereditary spherocytosis associated with deletion of human erythrocyte ankyrin gene on chromosome 8Nature, 1990